BEGIN:VCALENDAR VERSION:2.0 PRODID:-//jEvents 2.0 for Joomla//EN CALSCALE:GREGORIAN METHOD:PUBLISH BEGIN:VTIMEZONE TZID:Europe/Vienna BEGIN:STANDARD DTSTART:20211031T020000 RDATE:20220327T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:STANDARD DTSTART:20221030T020000 RDATE:20230326T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:STANDARD DTSTART:20231029T020000 RDATE:20240331T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:STANDARD DTSTART:20241027T020000 RDATE:20250330T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:STANDARD DTSTART:20251026T020000 RDATE:20260329T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:STANDARD DTSTART:20261025T020000 RDATE:20270328T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:STANDARD DTSTART:20271031T020000 RDATE:20280326T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:STANDARD DTSTART:20281029T020000 RDATE:20290325T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:STANDARD DTSTART:20291028T020000 RDATE:20300331T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:STANDARD DTSTART:20301027T020000 RDATE:20310330T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:STANDARD DTSTART:20311026T020000 RDATE:20320328T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:STANDARD DTSTART:20321031T020000 RDATE:20330327T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:STANDARD DTSTART:20331030T020000 RDATE:20340326T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:STANDARD DTSTART:20341029T020000 RDATE:20350325T030000 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:Europe/Vienna CET END:STANDARD BEGIN:DAYLIGHT DTSTART:20210606T090000 RDATE:20211031T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20220327T030000 RDATE:20221030T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20230326T030000 RDATE:20231029T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20240331T030000 RDATE:20241027T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20250330T030000 RDATE:20251026T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20260329T030000 RDATE:20261025T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20270328T030000 RDATE:20271031T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20280326T030000 RDATE:20281029T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20290325T030000 RDATE:20291028T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20300331T030000 RDATE:20301027T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20310330T030000 RDATE:20311026T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20320328T030000 RDATE:20321031T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20330327T030000 RDATE:20331030T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT BEGIN:DAYLIGHT DTSTART:20340326T030000 RDATE:20341029T020000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:Europe/Vienna CEST END:DAYLIGHT END:VTIMEZONE BEGIN:VEVENT UID: CATEGORIES:Symposium SUMMARY:What's new in immunotherapies 2022 LOCATION:London - UK DESCRIPTION;ENCODING=QUOTED-PRINTABLE: Synopsis\n\n Immunotherapy is a hot-topic field of research that has gener ated significant scientific interest and fuelled industrial innovation.\n \ n It has been demonstrated that small, drug-like molecules can be highly ef fective modulators of immune response pathways and that their molecular pro perties can be fine-tuned to enable excellent cell permeability and bioavai lability. This makes them ideal for use in the treatment of chronic conditi ons such as autoimmune and inflammation-related diseases. Excitingly, this approach also offers the possibility to treat cancer by harnessing the body ’s own immune system to fight tumours.\n \n This meeting will offer a broad introduction to those new to the topic and showcase recent innovatio ns by academic and industrial scientists in this exciting and rapidly expan ding field.\n Call for posters\n\n An abstract of maximum one A4 page or 30 0 words indicating title and authors should be sent to This email addr ess is being protected from spambots. You need JavaScript enabled to view i t. //  by Monday 31 January 2022 with the subject line &ld quo;What's New in Immunotherapies - poster abstract submission". P lease use the template attached here.\n Attendees\n\n The event is targeted at research students, researchers, academic and industrial scientists enga ged in all aspects of research into small molecule immunotherapy, and those interested in broadening their knowledge in this growing field.\n\n\n This event is being held back to back with "Targeting protein degradation 3 – from discovery to the clinic".\n Programme\n\n Confirmed spe akers: \n\n\n In vitro assays for immunotherapy drug discovery program s; overview and emerging areas\n Dr Rhoanne McPherson, Concept Life Science s                 \n \n Optimi sation of Mer/Axl kinase inhibitors for immuno-oncology\n Dr William McCoul l, AstraZeneca\n \n The discovery of BD2 selective BET inhibitors\n Dr Emma nuel Demont, GlaxoSmithKline\n \n First-in-class inhibitors of ERAP1 alter the immunopeptidome of cancer, driving a differentiated T cell response lea ding to tumour growth inhibition\n Dr Andrew Leishman, Grey Wolf therapeuti cs\n\n\n Discovery and Development of novel Small Molecule Inhibitors of IL -17\n Dr Anne Foley, UCB\n\n\n Professor Edward Tate, Imperial College\n\n\ n Enabling natural killer cell immunotherapy of cancer with small molecules \n Professor Matthew J. Fuchter, Imperial College\n\n\n Website\n\n\n   ;\n CONTACT:SCI DTSTAMP:20260829T185350Z DTSTART;TZID=Europe/Vienna:20220607T090000 DTEND;TZID=Europe/Vienna:20220607T180000 SEQUENCE:1 TRANSP:OPAQUE END:VEVENT END:VCALENDAR